financetom
Business
financetom
/
Business
/
Ericsson Agrees To Divest Subsidiary iconectiv; Expects $1B In Cash Benefit
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ericsson Agrees To Divest Subsidiary iconectiv; Expects $1B In Cash Benefit
Aug 19, 2024 7:42 AM

Ericsson shares are trading higher today. On Friday, the company inked a binding agreement with Koch Equity Development LLC regarding the sale of iconectiv.

iconectiv is a U.S. subsidiary of Ericsson acquired in 2012 and a provider of network number portability solutions and data exchange services. Since 2017, iconectiv has been co-owned with private equity firm Francisco Partners.

Ericsson expects to gain approximately SEK 10.6 billion ($1.0 billion) in cash from the deal after taxes, transaction expenses, and other liabilities.

Ericsson projects to record a one-off EBIT benefit of about SEK 8.8 billion ($0.8 billion) upon closing the transaction.

The transaction is expected to close in the first half of calendar 2025, pending customary regulatory approvals.

Richard Jacowleff, CEO of iconectiv, said, “iconectiv is excited to join KED along with the resources and capabilities they have to support our next chapter of growth. This acquisition marks a significant milestone in our journey, aligning us with a shareholder focused on long-term value creation that extends our track record as a trusted partner to service providers and regulators in the communications sector.”

As of June-end, Ericsson’s net cash stood at SEK 28.7 billion. 

Investors can gain exposure to the stock via IShares U.S. Digital Infrastructure And Real Estate ETF  and Defiance Connective Technologies ETF ( SIXG ) .

Price Action: ERIC shares are up 1.13% at $7.18 at the last check Monday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Read Next:

Ericsson And OPPO Ink Global 5G Patent Deal: Royalties and Innovation on the Horizon

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Protagenic Therapeutics Doses First Patient in Phase 1 Trial of Investigational Therapy PT00114; Shares Rise Pre-Bell
Protagenic Therapeutics Doses First Patient in Phase 1 Trial of Investigational Therapy PT00114; Shares Rise Pre-Bell
Aug 21, 2025
08:46 AM EDT, 08/21/2025 (MT Newswires) -- Protagenic Therapeutics ( PTIX ) said Thursday it has completed the first patient dosing in the multiple-dose portion of its ongoing phase 1 trial of PT00114, an investigational therapy based on a brain hormone that regulates stress and emotional balance. The company expects to complete dosing by the end of August, with topline...
Enphase Energy Achieves EU Cybersecurity Certification for All Eligible Products
Enphase Energy Achieves EU Cybersecurity Certification for All Eligible Products
Aug 21, 2025
08:45 AM EDT, 08/21/2025 (MT Newswires) -- Enphase Energy ( ENPH ) said Thursday that all its products subject to the European Union's Radio Equipment Directive Article 3.3 cybersecurity requirements are certified to be in compliance with the rules. The company said the new requirements, effective Aug. 1, introduces a cybersecurity foundation for connected devices sold in the European Union,...
OSI Systems' Fiscal Q4 Non-GAAP Earnings, Net Revenue Rise; Fiscal 2026 Outlook Set
OSI Systems' Fiscal Q4 Non-GAAP Earnings, Net Revenue Rise; Fiscal 2026 Outlook Set
Aug 21, 2025
08:46 AM EDT, 08/21/2025 (MT Newswires) -- OSI Systems ( OSIS ) reported fiscal Q4 non-GAAP earnings Thursday of $3.24 per diluted share, up from $2.84 a year earlier. Analysts polled by FactSet expected $3.19. Net revenue for the quarter ended June 30 was $505 million, compared with $480.9 million a year earlier. Analysts surveyed by FactSet expected $496.5 million....
Bausch Health Says Prescription Acne Gel Added to Canadian Provincial Drug Plans
Bausch Health Says Prescription Acne Gel Added to Canadian Provincial Drug Plans
Aug 21, 2025
08:47 AM EDT, 08/21/2025 (MT Newswires) -- Bausch Health ( BHC ) said Thursday its acne treatment Cabtreo is now covered under the public drug plans of Quebec and Saskatchewan, Canada. Cabtreo is a prescription topical gel indicated for patients 12 years and older with acne vulgaris and is already available under most private insurance plans, Bausch said. The company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved